Cargando…

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

SIMPLE SUMMARY: In the last years, treatments for recurrent glioblastoma patients have shown limited efficacy in terms of OS. In the REGOMA trial, regorafenib demonstrated encouraging results in this setting of population. Indeed, in this randomized, phase 2 study the OS was significantly improved i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombardi, Giuseppe, Caccese, Mario, Padovan, Marta, Cerretti, Giulia, Pintacuda, Giovanna, Manara, Renzo, Di Sarra, Francesca, Zagonel, Vittorina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471957/ https://www.ncbi.nlm.nih.gov/pubmed/34572958 http://dx.doi.org/10.3390/cancers13184731

Ejemplares similares

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Clinical Management of Diffuse Low-Grade Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study
por: Caccese, Mario, et al.
Publicado: (2023)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
por: Baro, Valentina, et al.
Publicado: (2022)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
por: Padovan, Marta, et al.
Publicado: (2023)

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
por: Tizianel, Irene, et al.
Publicado: (2022)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)

Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes
por: Gaudino, Simona, et al.
Publicado: (2022)

Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
por: Chiesa, Silvia, et al.
Publicado: (2022)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy
por: Magri, Sara, et al.
Publicado: (2021)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2020)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care
por: Ruggiero, Elena, et al.
Publicado: (2022)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans
por: Sansone, Giulio, et al.
Publicado: (2023)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma
por: Salvalaggio, Alessandro, et al.
Publicado: (2022)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Distinct MRI pattern of “pseudoresponse” in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review
por: Gatto, Lidia, et al.
Publicado: (2021)

An Overview of Intracranial Ependymomas in Adults
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells
por: Deshors, Pauline, et al.
Publicado: (2022)

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
por: Abrignani, Maurizio Giuseppe, et al.
Publicado: (2022)

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas
por: Zoccarato, Marco, et al.
Publicado: (2021)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Antigen rapid diagnostic test monitoring for SARS‐CoV‐2 in asymptomatic and fully vaccinated cancer patients: Is it cost‐effective?
por: Caccese, Mario, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dphuten3uhi143nbfcnovqc6lu